2 Stocks Near Their 52-Week Lows That Still Aren’t Worth Buying

In Q4, Elevidys’ revenue declined by about 2% year over year. Sarepta Therapeutics might have to deal with this issue for some time, and as long as it does, investors should stay away. The stock is …